Valneva : Production agreement with Batavia Biosciences
>New agreement with Batavia Biosciences in poliomyelitis - Valneva maintains the pace of its partnerships. This morning we learned of the signature of a new collaborative agreement with Batavia Biosciences. This agreement aims to accelerate the availability of its “inexpensive“ inactivated vaccine against poliomyelitis. More specifically, last year Batavia received a subsidy for the development of clinical batches of the vaccine against this pathology. Under...Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.